Oncology & Cancer

High risk of bowel cancer for gene carriers

Researchers from the University of Melbourne have found that screening for bowel cancer in genetically high-risk populations should begin early.

Oncology & Cancer

FDA: Cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Oncology & Cancer

New at-risk group identified for gastrointestinal stromal tumors

Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach ...

Oncology & Cancer

Botox for stomach cancer? No, but the research is fascinating

Amid continuing tales of global woe, Thursday morning's news carried one of those quirky 'fancy-that!' medical research stories that often captures the imagination, but which can inadvertently raise false hope in patients.

Medications

Cyramza approved for stomach cancer

(HealthDay)—Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach or of the area where the esophagus joins the stomach (the gastroesophageal junction).

page 14 from 23